The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.
Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.
The swelling started with almost no warning, then seven-year-old Fiona Wardman’s hand ballooned like a rubber glove hooked to ...
CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ: NASDAQ:KALV) has received Orphan Drug ...
Intellia Therapeutics (NTLA) announced the first patient has been dosed in the global Phase 3 study of NTLA-2002 for the treatment of ...
Lanadelumab effectively improved attack-free rates of type I and II hereditary angioedema patients, according to a study ...
KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The ...
Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.
Intellia Therapeutics Inc (NASDAQ:NTLA) outlined its strategic priorities for 2025, emphasizing the acceleration of ...
Intellia Therapeutics, Inc. (NASDAQ:NTLA) shares acquire momentum first thing. The Cambridge, Mass.-based Intellia, a leading clinical-stage gene editing company focused on revolutionizing medicine ...